Lantheus Holdings, Inc. (LNTH) Shares Bought by Morgan Stanley
Morgan Stanley increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 57.2% during the first quarter, Holdings Channel reports. The fund owned 360,113 shares of the medical equipment provider’s stock after buying an additional 130,992 shares during the period. Morgan Stanley’s holdings in Lantheus Holdings were worth $4,502,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Monashee Investment Management LLC acquired a new stake in Lantheus Holdings during the first quarter valued at approximately $5,313,000. Dimensional Fund Advisors LP acquired a new stake in Lantheus Holdings during the first quarter valued at approximately $3,646,000. Laurion Capital Management LP acquired a new stake in Lantheus Holdings during the first quarter valued at approximately $3,422,000. Spark Investment Management LLC raised its stake in Lantheus Holdings by 129.0% in the first quarter. Spark Investment Management LLC now owns 300,900 shares of the medical equipment provider’s stock valued at $3,761,000 after buying an additional 169,500 shares in the last quarter. Finally, Mckinley Capital Management LLC Delaware raised its stake in Lantheus Holdings by 109.4% in the first quarter. Mckinley Capital Management LLC Delaware now owns 281,221 shares of the medical equipment provider’s stock valued at $3,515,000 after buying an additional 146,936 shares in the last quarter. Institutional investors own 66.32% of the company’s stock.
Lantheus Holdings, Inc. (NASDAQ:LNTH) traded up 4.028% on Friday, reaching $18.725. 57,380 shares of the company’s stock were exchanged. The firm’s 50 day moving average is $17.92 and its 200 day moving average is $14.14. The stock has a market capitalization of $699.38 million, a P/E ratio of 25.581 and a beta of 0.91. Lantheus Holdings, Inc. has a 1-year low of $5.68 and a 1-year high of $20.45.
Lantheus Holdings (NASDAQ:LNTH) last released its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported $0.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.18. Lantheus Holdings had a negative return on equity of 37.47% and a net margin of 8.44%. The business had revenue of $88.83 million during the quarter, compared to analyst estimates of $80.56 million. During the same quarter last year, the company posted $0.24 EPS. Lantheus Holdings’s revenue for the quarter was up 13.9% on a year-over-year basis. Analysts expect that Lantheus Holdings, Inc. will post $1.07 EPS for the current year.
LNTH has been the topic of several recent research reports. Jefferies Group LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of Lantheus Holdings in a research report on Wednesday, April 26th. Zacks Investment Research upgraded shares of Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $17.00 price objective on the stock in a research report on Thursday, May 4th. Cantor Fitzgerald initiated coverage on shares of Lantheus Holdings in a research report on Monday, July 17th. They issued an “overweight” rating and a $22.00 price objective on the stock. Finally, Credit Suisse Group boosted their price objective on shares of Lantheus Holdings from $14.00 to $19.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 2nd. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Lantheus Holdings presently has an average rating of “Buy” and a consensus price target of $18.60.
In related news, Director David F. Burgstahler sold 3,000,000 shares of the stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $14.87, for a total value of $44,610,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Mary Anne Heino sold 10,000 shares of the stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $18.05, for a total value of $180,500.00. Following the completion of the transaction, the chief executive officer now owns 592,468 shares of the company’s stock, valued at approximately $10,694,047.40. The disclosure for this sale can be found here. Insiders sold a total of 3,040,000 shares of company stock valued at $45,252,800 in the last quarter. 2.30% of the stock is currently owned by corporate insiders.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH).
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.